MedTrace Logo

Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

NCT05467943 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-01-23

No results posted yet for this study

Summary

Treating Relapsed/Refractory Follicular Lymphoma with Tazemetostat

Conditions

  • Relapsed/Refractory Follicular Lymphoma With EZH2

Interventions

DRUG

Tazemetostat

All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Junning Cao, MD · Shanghai Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-29
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05467943 on ClinicalTrials.gov